Abstract: Objective To investigate the efficacy of lamivudine and transarterial chemoembolization in primary hepatocellular carcinomar. Methods 32 primary hepatocellular carcinomar patients with hepatitis B virus infection were retrospectively analyzed.They were divided into two groups. In research group,17 patients had received lamivudine and transarterial chemoembolization(TACE) and 15 patients in control group had undergone transarterial chemoembolization only. Results There were no significant differences between two groups in basic clinical materials,such as age,sex,tumor size, laboratory examination and performance status score,etc(P>0.05）.4 patients in the contral group had to stop treatment because of upper three grade liver function damagement with copies of HBV-DNA 10 folds higher than before. 2 patients in the research group had to stop treatment. One was because of three grade liver function damagement without copies of HBV-DNA higher than before,and the other one was because of serious infection in lung.The survival rates of 1 year, 2 years and the median survival time in reasearch group were 94.12%, 82.35% and 24.57 months, while that of contral group were 93.33%, 66.67% and 20.43 months, showing significance(P< 0.05). Conclusion TACE may promote the process of HBV replication.The activity of HBV can be inhibited by laminvudine to ensure TACE proceed smoothly and improve surviving.It deserves further study to identify the action of antivirus treatment in combined therapy in liver cancer.

Key words: primary liver cancer, interventionnal therapy, HBV, antivirus therapy